As of 2025-01-25, the EV/EBITDA ratio of Myriad Genetics Inc (MYGN) is -33.85. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. MYGN's latest enterprise value is 1,113.53 mil USD. MYGN's TTM EBITDA according to its financial statements is -32.90 mil USD. Dividing these 2 quantities gives us the above MYGN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 13.0x - 14.5x | 13.6x |
| Forward P/E multiples | 12.3x - 17.9x | 14.0x |
| Fair Price | (4.09) - (4.66) | (4.40) |
| Upside | -131.9% - -136.3% | -134.3% |
| Date | EV/EBITDA |
| 2025-01-23 | -33.68 |
| 2025-01-22 | -32.35 |
| 2025-01-21 | -33.15 |
| 2025-01-17 | -32.66 |
| 2025-01-16 | -33.02 |
| 2025-01-15 | -34.76 |
| 2025-01-14 | -36.23 |
| 2025-01-13 | -37.89 |
| 2025-01-10 | -39.41 |
| 2025-01-08 | -39.27 |
| 2025-01-07 | -37.94 |
| 2025-01-06 | -36.50 |
| 2025-01-03 | -36.20 |
| 2025-01-02 | -35.73 |
| 2024-12-31 | -36.31 |
| 2024-12-30 | -36.09 |
| 2024-12-27 | -35.51 |
| 2024-12-26 | -35.73 |
| 2024-12-24 | -36.39 |
| 2024-12-23 | -36.14 |
| 2024-12-20 | -35.34 |
| 2024-12-19 | -34.81 |
| 2024-12-18 | -35.04 |
| 2024-12-17 | -36.61 |
| 2024-12-16 | -37.44 |
| 2024-12-13 | -38.30 |
| 2024-12-12 | -38.49 |
| 2024-12-11 | -38.52 |
| 2024-12-10 | -40.82 |
| 2024-12-09 | -39.55 |
| 2024-12-06 | -40.24 |
| 2024-12-05 | -43.64 |
| 2024-12-04 | -44.31 |
| 2024-12-03 | -43.28 |
| 2024-12-02 | -44.55 |
| 2024-11-29 | -43.39 |
| 2024-11-27 | -43.42 |
| 2024-11-26 | -43.12 |
| 2024-11-25 | -41.84 |
| 2024-11-22 | -41.23 |
| 2024-11-21 | -40.21 |
| 2024-11-20 | -40.71 |
| 2024-11-19 | -39.88 |
| 2024-11-18 | -40.49 |
| 2024-11-15 | -40.57 |
| 2024-11-14 | -41.76 |
| 2024-11-13 | -42.04 |
| 2024-11-12 | -43.12 |
| 2024-11-11 | -46.27 |
| 2024-11-08 | -46.55 |